
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Singapore-based breast cancer AI startup FathomX raises SGD$ 2.24 M

September 1, 2022 | News

To increase the accuracy of mammograms in breast cancer detection using AI-integrated devices for detection, prevention, and diagnostics

FATHOMX



Singapore-based digital health startup FathomX, a spin-off company from the National University of Singapore(NUS) and National University Health System (NUHS), recently raised a Pre-series A fund of SGD$ 2.24 million in the lead up to Series A funding.

Through this funding, the startup will be able to harness the full potential of its digital artificial inteligent (AI) solution to read medical images including mammograms. The funding will further accelerate the pace of product development, regulatory approvals and broaden the platform for research and commercial collaborations. It will also facilitate the ongoing multi-centre validation study across eight regions in the Asia Pacific.

FathomX raised SGD$ 500,000 in a seed round in April 2021. Additionally, the I2Start Funding Programme, a tripartite initiative to support company formation around health and biomedical science innovations, was awarded to allow the building of digital breast imaging AI for diagnosing cancer. Initial funding partners include the Singapore-MIT Alliance for Research and Technology Centre (SMART), the National Health Innovation Centre (NHIC), Enterprise Singapore (EnterpriseSG) and the National University of Singapore (NUS). FathomX also partnered A*STAR's Diagnostics Development Hub (DxD Hub) and Hewlett Packard Enterprise to productise the Software as a Medical Device (SaMD), FxMammo.